Cargando…

Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells

Using seven monoclonal SN38-resistant subclones established from ME180 human cervical squamous cell carcinoma cells, we examined the demethylation effects of 5-aza-2′-deoxycytidine (5-aza-CdR) on the SN38-sensitivity of the cells as well as the expression of death-associated protein kinase (DAPK) in...

Descripción completa

Detalles Bibliográficos
Autores principales:	TANAKA, TETSUJI, BAI, TAO, TOUJIMA, SAORI, UTSUNOMIYA, TOMOKO, MATSUOKA, TOSHIHIDE, KOBAYASHI, AYA, YAMAMOTO, MADOKA, SASAKI, NORIYUKI, TANIZAKI, YUKO, UTSUNOMIYA, HIROTOSHI, TANAKA, JUNKO, YUKAWA, KAZUNORI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2012
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583479/ https://www.ncbi.nlm.nih.gov/pubmed/22246465 http://dx.doi.org/10.3892/or.2012.1628

Ejemplares similares

Investigation into the Efficacy of Val-SN-38, a Valine-Ester Prodrug of the Anti-Cancer Agent SN-38
por: Kwak, Eun-Young, et al.
Publicado: (2012)

An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells
por: Yashiro, M, et al.
Publicado: (2011)

Synthesis, characterization, and evaluation of mPEG–SN38 and mPEG–PLA–SN38 micelles for cancer therapy
por: Xie, Jing, et al.
Publicado: (2016)

Single Protein Encapsulated SN38 for Tumor-Targeting Treatment
por: Yu, Changjun J., et al.
Publicado: (2023)

Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38
por: Mathijssen, R H J, et al.
Publicado: (2002)

In vitro and in vivo evaluation of SN-38 nanocrystals with different particle sizes
por: Chen, Min, et al.
Publicado: (2017)

Carbon dots conjugated to SN38 for improved colorectal anticancer therapy
por: Mattinzoli, Deborah, et al.
Publicado: (2022)

Synthesis and Antitumor Evaluation of Biotin-SN38-Valproic Acid Conjugates
por: Dai, Yi, et al.
Publicado: (2023)

A Limited Sampling Model for Estimating Pharmacokinetics of CPT‐11 and Its Metabolite SN‐38
por: Sasaki, Yasutsuna, et al.
Publicado: (1995)

Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
por: van Ark-Otte, J., et al.
Publicado: (1998)

Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates
por: Liu, Lianqi, et al.
Publicado: (2021)

Structural Modification Endows Small-Molecular SN38 Derivatives with Multifaceted Functions
por: Dai, Yi, et al.
Publicado: (2023)

Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines
por: Jandu, Haatisha, et al.
Publicado: (2016)

A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38
por: Sasaki, Yasutsuna, et al.
Publicado: (1995)

Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy
por: Bi, Ye, et al.
Publicado: (2018)

Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study
por: Wu, Chan, et al.
Publicado: (2018)

Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy
por: Xing, Jing, et al.
Publicado: (2019)

Pharmacological Correlation between Total Drug Concentration and Lactones of CPT‐11 and SN‐38 in Patients Treated with CPT‐11
por: Sasaki, Yasutsuna, et al.
Publicado: (1995)

SW-620 cells treated with topoisomerase I inhibitor SN-38: gene expression profiling
por: Souza, Vinicius, et al.
Publicado: (2005)

Human Serum Albumin Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN38) for Cancer Treatment
por: Sepehri, Nima, et al.
Publicado: (2014)

The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer
por: Lin, Xue, et al.
Publicado: (2015)

Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells
por: Dai, Xiao-Yang, et al.
Publicado: (2016)

Irinotecan metabolite SN38 results in germ cell loss in the testis but not in the ovary of prepubertal mice
por: Lopes, Federica, et al.
Publicado: (2016)

Effective Irinotecan (CPT‐11)‐containing Liposomes: Intraliposomal Conversion to the Active Metabolite SN‐38
por: Sadzuka, Yasuyuki, et al.
Publicado: (1999)

SN38 loaded nanostructured lipid carriers (NLCs); preparation and in vitro evaluations against glioblastoma
por: Shirazi, Ali Sabouri, et al.
Publicado: (2021)

Cholesterol-Inulin Conjugates for Efficient SN38 Nuclear Delivery: Nanomedicines for Precision Cancer Therapy
por: Mauro, Nicolò, et al.
Publicado: (2022)

5-Fluorouracil and irinotecan (SN-38) have limited impact on colon microbial functionality and composition in vitro
por: Vanlancker, Eline, et al.
Publicado: (2017)

Inhibition of UDP‐glucuronosyltransferase by Aglycons of Natural Glucuronides in Kampo Medicines Using SN‐38 as a Substrate
por: Yokoi, Tsuyoshi, et al.
Publicado: (1995)

One-step mechanochemical preparation and prominent antitumor activity of SN-38 self-micelle solid dispersion
por: Sun, Xuanrong, et al.
Publicado: (2019)

Synthesis and Biological Evaluation of Novel 10-Substituted-7-ethyl-10-hydroxycamptothecin (SN-38) Prodrugs
por: Zhou, Mo, et al.
Publicado: (2014)

The Mode of SN38 Derivatives Interacting with Nicked DNA Mimics Biological Targeting of Topo I Poisons
por: Bocian, Wojciech, et al.
Publicado: (2021)

Novel pH-Responsive Cubosome and Hexosome Lipid Nanocarriers of SN-38 Are Prospective for Cancer Therapy
por: Rajesh, Sarigama, et al.
Publicado: (2022)

A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients
por: Hamaguchi, Tetsuya, et al.
Publicado: (2018)

Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines
por: Poele, R H te, et al.
Publicado: (1999)

IT-141, a Polymer Micelle Encapsulating SN-38, Induces Tumor Regression in Multiple Colorectal Cancer Models
por: Carie, Adam, et al.
Publicado: (2011)

Injectable SN-38-embedded Polymeric Microparticles Promote Antitumor Efficacy against Malignant Glioma in an Animal Model
por: Tseng, Yuan-Yun, et al.
Publicado: (2020)

High Potency of SN-38-Loaded Bovine Serum Albumin Nanoparticles Against Triple-Negative Breast Cancer
por: Lin, Hsin-Che, et al.
Publicado: (2019)

Novel Nontoxic 5,9-Disubstituted SN38 Derivatives: Characterization of Their Pharmacological Properties and Interactions with DNA Oligomers
por: Bednarek, Elżbieta, et al.
Publicado: (2021)

Aptamer-functionalized mesenchymal stem cells-derived exosomes for targeted delivery of SN38 to colon cancer cells
por: Pishavar, Elham, et al.
Publicado: (2023)

SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair
por: Lin, Shengbin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gjkl3m3fidv6f2ap1tajhel17d